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Abstract
Objective—To examine the association of smoking with clinical and serologic features in African
Americans with recent-onset rheumatoid arthritis (RA) and to explore whether this association is
dependent on the presence of the HLA-DRB1 shared epitope (SE).
Methods—In African Americans with recent-onset RA (n = 300), we examined the association of
cigarette smoking (current vs. past vs. never and pack-years of exposure) with anti-CCP antibody,
rheumatoid factor (RF) (-IgM and -IgA), rheumatoid nodules, and baseline radiographic erosions
using logistic and cumulative logistic regression (adjusting for SE status). We also examined for
evidence of interaction between smoking status and SE for all outcomes.
Results—Although there was no association with RF-IgA seropositivity, current smokers were
approximately twice as likely as never smokers to have higher IgA-RF concentrations (based on
tertiles; OR = 1.74; 95% CI 1.05–2.88) and nodules (OR = 2.43; 95% CI 1.13–5.22). These
associations were most pronounced in those with more than 20 pack-years of exposure. There was
no association of smoking status or cumulative tobacco exposure with anti-CCP antibody, IgM-RF,
or radiographic erosions. There was also no evidence of a biologic or statistical SE-smoking
interaction for any of the outcomes examined.
Conclusion—This is the first study to systematically examine the association of cigarette smoking
with RA-related features in African Americans. Cigarette smoking is associated with both
subcutaneous nodules and higher serum concentrations of IgA-RF in African Americans with RA,
associations that may have important implications for long-term outcomes in this population.
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Since the first report by Vessey nearly twenty years ago 1, cigarette smoking has been shown
in numerous investigations to be associated with rheumatoid arthritis (RA) susceptibility 2–
10. In a national study of disease-discordant monozygotic twins, smoking was associated with
a twelve-fold increased risk of RA 11, an association that appears to be most pronounced in
those with long-term exposure (> 20 years duration) 7,12,13. The impact of smoking on RA risk
also appears to be mediated by certain genetic risk factors with the HLA-DRB1 shared epitope
(SE) being the most notable. In a recent case-control study, there was no significant association
of smoking with seropositive RA in cases without the SE. Ever having smoked, however, was
associated with a more than six-fold increased risk of anti-CCP (cyclic citrullinated peptide)
antibody-positive RA among those with a single SE-containing HLA-DRB1 allele and a more
than 20-fold increased risk in those with two SE-containing alleles 2.
In addition to its association with disease risk, smoking also appears to be an important
determinant of RA disease expression. Specifically, smoking has been associated with the
presence of extra-articular disease manifestations 14 (including rheumatoid nodules),
radiographic severity 15–17, and serum rheumatoid factor (RF) 15,16,18,19. Reports examining
associations of smoking with anti-CCP antibody in RA have been inconsistent with at least
one study showing a positive association 20 while another showed no such association 21.
Studies to date examining the association of smoking with RA disease features have almost
exclusively involved subjects of European ancestry. The lack of such studies among ethnic/
racial minorities is relevant for three reasons: 1) the prevalence of smoking in African
Americans appears to be increasing 22 while ‘quit rates’ in African Americans are lower
compared to Caucasians 23, 2) disease characteristics related to smoking portend a poor
outcome in RA 24–30, and 3) smoking appears to have a disproportionately negative impact on
minority patients with select chronic conditions 31,32 The objective of this cross-sectional study
was to examine the association of cigarette smoking with disease expression in a group of well
characterized African Americans with recent-onset RA.
Patients and Methods
Study Population
RA cases (n = 300) were participants in the Consortium for the Longitudinal Evaluation of
African-Americans with Early Rheumatoid Arthritis (CLEAR)33–35. Subjects were enrolled
through one of four sites in the southeast U.S. (University of Alabama at Birmingham, Emory
University, Medical University of South Carolina, and the University of North Carolina). The
study was approved by the Institutional Review Board (IRB) at each participating center and
all study subjects provided informed written consent prior to participation. Cases satisfied the
American College of Rheumatology (ACR) RA classification criteria 36, had less than two
years of disease duration, and self-reported African American race/ethnicity (there was no
requirement for additional first- or second-degree relatives of African American ancestry).
Smoking status (current, former, never) was collected at the time of enrollment and for ever
smokers, pack-years of smoking served as a measure of cumulative exposure. All subjects
underwent formal examination that included an assessment for the presence of subcutaneous
nodules. Radiographs of the hands and wrists were obtained at baseline (defined as < 2 years
duration, with a mean of 13.7 months disease duration) and scored using the van der Heijde
modified Sharp score 37. Validated scores were available for 192 of the 300 cases under study
for whom radiographs were obtained. Subjects with available scores were classified as having
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either erosive disease (Sharp erosion score > 0) or non-erosive disease (Sharp erosion score =
0) at baseline.
Autoantibody Measurement
Autoantibody measurements, including anti-CCP antibody and RF isotypes, were performed
as previously reported 33. Anti-CCP (IgG) antibodies were measured in arbitrary units (U) per
ml using a commercially available second generation enzyme linked immunosorbent assay
(Diastat, Axis-Shield Diagnostics Ltd., Dundee, Scotland, UK) and were considered to be
positive at a cut-off value ≥ 5 U/ml 33. RF isotypes (IgA and IgM) were measured in
international units (IU) per ml and were assessed using commercially available ELISA
(INOVA Diagnostics Inc., San Diego, CA, USA). Positive tests were defined by levels of ≥
10.8 IU/ml for IgA-RF and ≥ 9.5 IU/ml for IgM-RF 33.
HLA-DRB1 Genotyping
High resolution HLA-DRB1 genotyping was performed as recently described with results
showing a higher frequency of SE-containing alleles in African American cases compared to
controls 38. In brief, genotyping was completed through DNA sequencing of exon 2 using the
alleleSEQR HLA-DRB1 reagent kit and protocol (Atria Genetics, South San Francisco, CA).
After PCR amplification, sequencing was performed on an ABI 377 automated sequencer (PE
Applied Biosystems, Foster City, CA). An additional sequence reaction was performed to
analyze codon 86 sequences, thus allowing for the resolution of ambiguous results for some
of the exon 2 sequences. The sequences were analyzed using Assign SBT3 Software (Conexio
Genomics, Australia), enabling assignment of genotypes based on recent library file of HLA-
DRB1 alleles. This method detects all SE positive alleles. When necessary, group-specific
amplifications were performed and sequence analysis conducted to differentiate among alleles
within a specific group.
Statistical Analysis
Dichotomous outcomes including autoantibody status (positive vs. negative), the presence of
nodules, and the presence of radiographic erosions were compared by smoking status using
the Chi-square test in unadjusted analyses and subsequently by using multivariable logistic
regression and adjusting for the presence of SE. In an additional analysis, we examined the
association of smoking status with anti-CCP antibody positivity after stratifying subjects by
SE status. The odds of having higher autoantibody concentrations or higher baseline erosion
scores were compared among groups defined by baseline smoking status using cumulative
logistic regression models (using the cumulative logit link function to generate a cumulative
odds ratio (OR) 39) adjusting for SE status; for this analysis outcome variables were categorized
into tertiles. The OR and 95% CI reflect the cumulative odds of having an outcome value in
the highest tertile vs. the low/medium tertiles or an outcome value in either the high/medium
tertiles vs. the lowest tertile. In secondary analyses, we also examined the association of
cumulative exposure categories (never, < 10, 10–20, and > 20 pack-years) with the outcomes
of interest. Of 300 study participants, fourteen subjects were excluded from multivariable
analyses due to missing values for SE (n = 10) or smoking status (n = 4). Additional subjects
with missing data for nodules (n = 2) and erosions (n = 94) were excluded from multivariable
analyses examining the association of smoking with these outcomes. There were an additional
six subjects with a history of smoking but missing cumulative exposure data excluded from
analyses examining the association of smoking pack-years with the outcomes of interest.
Gene-environment interactions (SE-smoking) were examined in two ways as reviewed
elsewhere 40. Based on recent reports of disease susceptibility 2,6,41, we assessed biologic
(additive) interaction between ever smoking (current or past smoking combined) and SE status
by examining for evidence of departure from additivity of effects as the interaction criteria as
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described by Rothman et al 42. Using this approach 40,43, we calculated the attributable
proportion due to interaction (AP; where an AP = 0 corresponds to no interaction and an AP
=1.0 corresponds to ‘complete’ interaction) and a corresponding 95% confidence interval using
the method of Hosemer and Lemeshow 44. To assess for evidence of statistical (or
multiplicative) interaction, we modeled the SE-smoking product terms, using a p-value of <
0.05 as the threshold for significance. All analyses were conducted using SAS v9.1 (SAS Inc.,
Cary, NC).
Results
Subject characteristics are summarized in Table 1.
African Americans study subjects were comprised predominantly of women (83%) and had a
mean age of approximately 51 years. Almost half of subjects were ever smokers, 42% were
SE positive, 27% had baseline radiographic erosions, and 14% had rheumatoid nodules. Only
23 subjects (8%) carried two SE containing alleles. Seropositivity was observed in 62% of
subjects for anti-CCP antibody, 67% for IgA-RF, and 70% for IgM-RF.
The associations of smoking status with autoantibody status (positive vs. negative) and the
presence of both nodules and erosions are summarized in Table 2.
In univariate or SE-adjusted analyses, there was no association of smoking status with
seropositivity for anti-CCP antibody, IgA-RF, or IgM-RF nor was there an association of
smoking with the presence of radiographic erosions. While there was no risk associated with
past smoking, current smokers were more than twice as likely as never smokers (OR = 2.43;
95% CI 1.13–5.22) to have rheumatoid nodules after adjusting for SE status. In analysis
stratified by SE status, there were also no significant associations of smoking status with anti-
CCP antibody positivity (Table 2).
Our results were similar when examining the association of cumulative smoking exposure with
the dichotomous outcomes of interest. There were no associations of smoking pack-years with
autoantibody seropositivity or the presence of radiographic erosions (Table 2). However,
compared to never smokers, RA cases with high cumulative exposure (> 20 pack-years) were
significantly more likely to have rheumatoid nodules (SE-adjusted OR = 2.65; 95% CI 1.10–
6.37) while cases with intermediate levels of exposure (10–20 pack-years) showed a trend
towards higher risk (OR = 2.01; 95% CI 0.71–5.75).
There was no association of smoking status with higher serum concentrations of anti-CCP
antibody or IgM-RF based on tertiles, nor was there an association with radiographic erosion
scores (Table 3). After adjusting for SE and compared to never smokers, current smokers were
approximately two-times more likely to have higher concentrations of IgA-RF (OR = 1.74;
95% CI 1.05–2.88). The risk of higher IgA-RF concentrations appeared to be most pronounced
in those with more than 20 pack-years of cumulative exposure (SE-adjusted OR = 2.79; 95%
CI 1.50–5.17) while those with low and intermediate levels of cumulative exposure displayed
no such risk (Table 3).
There was no evidence of statistical (multiplicative) interaction between smoking status (never,
past, current) and SE for any of the outcomes examined (either dichotomous or ordered
categorical outcomes) with p-values > 0.10 for all smoking-SE product terms (data not shown).
Likewise, there was no evidence of significant biologic (additive) interaction between ever
smoking and SE in our models examining dichotomous outcomes. In each circumstance, the
95% CI for the attributable proportion (AP) due to interaction included zero. Results from the
assessments of possible biologic interactions are summarized in Table 4.
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To our knowledge, this is the first study to examine the associations of cigarette smoking with
RA-related disease characteristics in African Americans. In this population, current smoking
is positively associated with the presence of both rheumatoid nodules and higher serum
concentrations of IgA-RF, associations that appear to be independent of underlying SE status
and most pronounced in those with higher levels of cumulative tobacco exposure. In contrast,
our results suggest that smoking is not a major determinant of IgM-RF or anti-CCP antibody
in African Americans with RA, either in terms of seropositivity or higher serum concentrations.
In contrast to subjects of European ancestry with both early 16 and established disease 15,17,
smoking does not appear to be strongly associated with the presence or extent of baseline
radiographic erosions among African Americans with recent-onset RA.
The association of cigarette smoking with rheumatoid nodules and higher IgA-RF
concentrations may have important implications in this population. IgA-RF, for instance, has
been shown in RA patients of European/Caucasian descent to be an independent predictor of
severe joint damage in established disease and has been associated with both poor functional
status and extraarticular disease including pulmonary involvement 45–48. In one study, 80%
of RA patients with elevated IgA-RF concentrations had one or more extraarticular disease
manifestations compared to only 21% of those with increased concentrations of IgM-RF but
normal IgA-RF 48, highly relevant given the association of extraarticular findings with disease-
related mortality 49. Rheumatoid nodules, the most common extraarticular disease
manifestation, have been associated with a more than four-fold increased risk of mortality in
men with RA from the U.K. Norfolk Arthritis Registry 50.
It remains unknown whether smoking is a risk factor in African Americans for the development
of RA (disease characterized by the presence of higher IgA-RF values) or whether smoking or
its byproducts stimulate specific autoantibody expression. In a cross-sectional study of subjects
of European ancestry without RA, both IgA-RF (34.4%) and IgM-RF (34.1%) were
significantly more likely to be positive in smokers compared to non-smokers (21.9%),
suggesting that smoking may have a direct effect on humoral immunity irrespective of disease
status 51. Padyukov et al found that smoking increases the risk of developing RF-positive RA
but not seronegative RA, a risk that was confined to those positive for SE 6. Although Padyukov
and colleagues did not examine specific RF isotypes or anti-CCP antibody, their results support
the existence of SE-smoking interaction in the risk of RF-positive disease. In a more recent
study, Klareskog et al found a similar association of smoking for the development of anti-CCP
antibody positive disease, a risk also limited to SE-positive subjects 2. Based on subanalyses
in subjects discordant for anti-CCP antibody and RF, their results also suggest that the
development of anticitrulline immunity is the ‘primary’ pathogenic event in smokers carrying
SE while the development of RF more likely represents a ‘secondary’ phenomenon.
In contrast to recent reports examining disease susceptibility 2,6,41 in Caucasians and the effect
of smoking on autoantibody expression 20, we found no evidence to support the role of a SE-
smoking interaction in RA disease expression among African Americans. However, our results
are consistent with recent findings from three large North American Caucasian RA cohorts,
showing no major SE-smoking interaction for anti-CCP antibody expression 52. In a report of
407 Dutch subjects with recent-onset disease, a history of tobacco exposure was associated
with an increased odds of anti-CCP antibody positivity in SE positive RA subjects but not in
those negative for SE 20. In contrast to our study, biologic interaction between SE and smoking
in the study of Linn-Rasker et al 20 was defined as being present because the odds of having
anti-CCP antibody for subjects having both tobacco exposure and SE (OR = 5.27; 95% CI
2.37–11.80) was higher than the summed odds ratios of subjects with only tobacco exposure
(OR = 1.07; 95% CI 0.43–2.65) or SE alone (OR = 2.49; 95% CI 1.18–5.31). In post-hoc
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analyses of these data, there was no evidence of statistical interaction (p-value of interaction
term = 0.2) while the attributable proportion (AP) due to interaction was estimated to be 0.5
53,54. Even with the use of the less stringent definition 20, our results still provide no conclusive
evidence of an interaction between smoking and SE for the development of anti-CCP antibody,
RF (either IgM or IgA isotype), or radiographic erosions in African Americans with RA
(although suggesting the presence of a borderline SE-smoking interaction for the presence of
nodules).
Although our study includes the largest African American RA cohort systematically examined
to date, it is likely that our analysis was not adequately powered to detect this gene-environment
interaction. Because these subjects were recruited primarily from academic rheumatology
practices, it is possible that these results are not generalizable to other African American
populations with RA. Given the lower prevalence of HLA-DRB1 alleles in African American
cases relative to Caucasians with RA 55, we were not able to adequately examine the impact
of SE ‘dose’ nor were we able to fully evaluate the risk conferred by specific HLA-DRB1
alleles. This limitation is noteworthy because different SE alleles appear to differ in their
interaction with smoking and predisposition to autoantibodies in patients of European ancestry
56. It is possible that discrepant results observed across different populations (African American
vs. Caucasian and/or North American vs. European) may be due to other ‘unmeasured’ risk
factors involved in RA pathogenesis that are more common to select ethnic/racial groups (i.e.
additional genes and/or environmental triggers)
In summary, the data presented in this report show that cigarette smoking is associated with
select disease characteristics in African Americans with recent onset RA, features that include
higher serum concentrations of IgA-RF and the presence of subcutaneous nodules. As reported
in other studies of disease susceptibility, the associated risk of smoking appears to be greatest
among subjects with the highest levels of cumulative exposure. Further studies that include a
larger number of well-characterized cases and controls with extended follow-up will be needed
to better define the complex relationship of smoking with pre-disposing risk alleles in RA
susceptibility and disease expression in African Americans.
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Table 1
Subject characteristics of African Americans with recent onset rheumatoid arthritis (n = 300)
Characteristic* Mean (SD) or Number (%)
Female sex 246 (82%)
Age, years 50.6(13.5)





 Ever smoked, < 10 pack-years 63 (22%)
 Ever smoked, 10–20 pack-years 34(12%)
 Ever smoked, > 20 pack-years 51 (18%)
Shared epitope positive 123 (42%)
Anti-CCP antibody positive 186 (62%)
RF-IgA positive 202 (67%)
RF-IgM 211 (70%)
Baseline Radiographic erosions 51 (27%)
Nodules 41 (14%)
*
Denominator as noted with exception of missing values for shared epitope status (n = 10), age (n = 2), smoking status (n = 4), pack-years of smoking (n
= 6) among ever smokers, disease duration (n = 2), nodules (n = 5), and radiographic erosions (n = 108 radiographs unscored at time of analysis); CCP =
cyclic citullinated peptide
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Table 3
Associations of smoking status (current vs. past vs. never) and categories of cumulative smoking exposure (pack-years)
with higher tertiles of autoantibody concentrations and modified Sharp erosion scores among African Americans with
recent-onset rheumatoid arthritis; cumulative logistic regression models (using cumulative logit link function to
generate a cumulative OR and 95% CI) adjusted for presence of shared epitope (SE)*
Anti-CCP Antibody RF-IgM RF-IgA Erosion Score
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Smoking Status (n =286) (n =286) (n =286) (n = 192)
 Never Referent Referent Referent Referent
 Past 1.13 (0.65–1.94) 1.15(0.67–1.98) 1.51 (0.88–2.61) 1.24 (0.56–2.71)
 Current 1.11 (0.67–1.84) 1.27 (0.77–2.09) 1.74 (1.05–2.88) 1.05 (0.50–2.21)
Pack-Yearst† (n =280) (n =280) (n =280) (n =189)
 Never Referent Referent Referent Referent
 < 10 1.21 (0.69–2.12) 1.05 (0.60–1.83) 1.25 (0.71–2.18) 0.92 (0.40–2.14)
 10–20 0.87 (0.43–1.77) 1.05 (0.52–2.11) 1.30 (0.64–2.62) 0.98 (0.35–2.71)
 > 20 1.27 (0.70–2.78) 1.65 (0.90–3.02) 2.79 (1.50–5.17) 1.18 (0.61–2.26)
*
CCP = cyclic citrullinated peptide; RF = rheumatoid factor; outcome variables categorized into tertiles; OR (and 95% CI) reflects the cumulative odds
of having an outcome value in the highest tertile vs. the low/medium tertiles or an outcome value in either the high/medium tertiles vs. the lowest tertile.
†
Six subjects a known smoking history (3 with available erosion scores) were excluded from analysis due to missing values for pack-years of smoking
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